Organization | G1 Therapeutics, Inc.

G1 Therapeutics, Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Durham North Carolina United States (2008)

Organization Overview

First Clinical Trial

2014

NCT02243150

First Marketed Drug

2021

trilaciclib (Cosela)

First NDA Approval

2021

trilaciclib (Cosela)

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

G1 THERAP | G1 Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

trilaciclib (Cosela) (2021 NDA)

Drugs in Phase 4 Trials (2)

topotecan (hycamtin) (2 trials)

trilaciclib (Cosela) (17 trials)

Drugs in Phase 3 Trials (2)

carboplatin (paraplatin) (7 trials)

gemcitabine (gemzar) (4 trials)

Drugs in Phase 2 Trials (14)

atezolizumab (Tecentriq) (1 trial)

avelumab (bavencio) (1 trial)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (2 trials)

fulvestrant (faslodex) (1 trial)

g1t38 (3 trials)

lurbinectedin (Zepzelca) (1 trial)

osimertinib (tagrisso) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (2 trials)

sacituzumab govitecan (Trodelvy) (1 trial)

Drugs in Phase 1 Trials (2)

g1t48 (1 trial)

palbociclib (ibrance) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Carcinoma, Ductal (Phase 2)

Carcinoma, Ductal, Breast (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 21
# of Trial APIs: 20